Nurix Therapeutics Inc

NASDAQ:NRIXUnited States

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Contact Information

Headquarters

1700 Owens St Ste 205SAN FRANCISCO, CA, United States 94158-0006

Phone

415-660-5320

Fax

415-525-4200

Executives

Independent Chairman of the Board

David Lacey

President, Chief Executive Officer, Director

Arthur Sands

Chief Financial Officer

Hans van Houte

Chief Scientific Officer

Gwenn Hansen

Chief Legal Officer, Chief Compliance Officer, Secretary

Christine Ring